Skip to main content

Table 5 Clinical and demographic characteristics of patients with and without nephrotoxicity

From: Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study

 

Patients without nephrotoxicity (n = 76)

Patients with nephrotoxicity (n = 26)

P

Patients without nephrotoxicity (n = 52)

Patients with nephrotoxicity (n = 50)

P

 

Day 7

 

EOT

 

Age, years*

66.5 (24–91)

73 (41–84)

0.036

65 (24–91)

72.5 (30–87)

0.016

Male sex

61 (80.3)

18 (69.2)

0.281

40 (76.9)

39 (49.4)

1

Charlson Index*

4.12 ± 2.58

5.5 ± 2.34

0.031

3.6 ± 2.4

5.36 ± 2.3

0.001

APACHE II

14.9 ± 6.4

14.8 ± 7

0,32

15.3 ± 6

14.2 ± 7

0,16

Clinical status:

      

- Severe sepsis

39 (51.3)

9 (34.6)

0.175

24 (46.2)

24 (48)

1

- Shock

7 (9.2)

1 (3.8)

0.457

7 (13.5)

1 (2)

0.06

Acute renal failure at baseline

11 (14.5)

4 (15.4)

1

4 (7.7)

11 (22)

0.052

1CKD at baseline

17 (22.3)

6 (23)

1

11 (21.15)

12 (24)

0.81

Albumin*

2.8 ± 0.62

2.5 ± 0.62

0.047

2.8 ± 0.62

2.6 ± 0.62

0.031

1BMI (Kg/m2)*

25.6 ± 5.9

24.3 ± 5.03

0.26

25.2 ± 5

25.4 ± 6.35

0.75

3CMS total dose (MU)*

35.1 ± 15.15

42 ± 15.84

0.06

97.3 ± 106.35

103.9 ± 78.5

0.047

Duration of CMS treatment, days*

   

18.7 ± 16.6

21.02 ± 14.42

0.047

4Cmin, mg/mL*

0.78 (0.11-3.2)

3.11 (0.45-5.99)

<0.0001

0.7 (0.11-5.7)

1.18 (0.16-5.99)

<0.0001

5Cmax, mg/mL*

0.78 (0.15-3)

3.2 (0.68-6.62)

<0.0001

0.74 (0.15-6.10)

1.81 (0.16-6.62)

<0.0001

Concomitant aminoglycoside use

24 (31.6)

8 (30.8)

1

16 (30.8)

16 (32)

1

Concomitant vancomycin use

8 (10.5)

1 (3.8)

0.442

3 (5.8)

6 (12)

0.314

Concomitant 6NSAID use

11 (14.5)

4 (15.4)

1

3 (5.8)

12 (24)

0.012

Concomitant loop diuretic use

31 (40.8)

15 (57.7)

0.172

16 (30.8)

30 (60)

0.005

Other concomitant nephrotoxic drugs

17 (22.4)

4 (14.4)

0.579

13 (25)

8 (16)

0.33

≥ 2 nephrotoxic drugs

37 (48.7)

13 (50)

1

20 (38.5)

30 (60)

0.047

  1. Data are n (%) except where indicated.
  2. * Median (interquartile range).
  3. ** Mean ± SD.
  4. 1CKD: chronic kidney disease. 2BMI: body mass index. 3CMS:colistinmethanesulfonate sodium. 4Cmin: colistin trough plasma concentrations at steady state. 5Cmqx: colistin maximum plasma concentrations at steady state. 6NSAID: non-steroidal anti-inflammatory drugs.